Crizanlizumab

(Adakveo®)

Adakveo®

Drug updated on 11/14/2023

Dosage FormInjection (intravenous: 10 mg/mL)
Drug ClassSelectin blockers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.